Navigation Links
IRIDEX Announces Automatic Conversion of Series A Preferred Stock to Common Stock
Date:6/11/2013

MOUNTAIN VIEW, Calif., June 11, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has converted all outstanding shares of its Series A Preferred Stock into 1,000,000 shares of its common stock. The Series A Preferred shares were issued to BlueLine Capital Partners LP (BlueLine) as part of a private placement agreement that occurred in 2007. The Certificate of Designation provides that the Series A Preferred shares will automatically convert into common stock if IRIDEX common stock trades above $5.00 for 30 consecutive trading days.

"This is a positive development for the Company and has been a goal since BlueLine invested in IRIDEX in a private placement and the preferred shares were issued in 2007," Will Moore President and CEO of IRIDEX said. "I want to thank BlueLine for their initial and ongoing support that has allowed us to get to this point. The conversion simplifies our capital structure, is non-dilutive and is an indication that we have made great strides in the past year in meeting commercial and operational milestones and winning investor confidence. The Series A Preferred Stock has always been included in the diluted share count and will be part of the basic and diluted share count going forward."

As a result of the conversion, the separate right of the holders of Series A Preferred Stock to a senior liquidation preference and to appoint a second board member, subject to the approval of the Company, have also ceased.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, w
'/>"/>

SOURCE IRIDEX Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit
2. IRIDEX Reports 2013 First Quarter Results
3. IRIDEX Announces Receipt of Large Orders for Laser Systems from Developing Countries
4. IRIDEX Announces First Quarter 2013 Conference Call and Release Date
5. IRIDEX Announces Global Distribution and Supply Agreement with Peregrine Surgical, Ltd.
6. IRIDEX Reports Record 2012 Fourth Quarter Results
7. IRIDEX Announces Fourth Quarter and Full Year 2012
8. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
9. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
10. IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
11. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... , Dec. 22, 2014   TRU-D SmartUVC ... UV disinfection robot, announced today that the General Services ... through November 2019.   This newly formed ... all levels of government purchasers, including Department of Veteran ... as Homeland Security contacts purchasing solutions for the Ebola ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... demonstrates important role of, radioimmunotherapy in converting partial ... and ... SEATTLE, March 17 Cell Therapeutics, Inc.,(CTI) (Nasdaq: ... with previously,untreated follicular non-Hodgkin,s lymphoma (NHL) treated with ...
... Data from Pivotal Trial Presented at Annual Meeting of ... American Association for Geriatric Psychiatry --, ... (Nasdaq: MDVN ) today announced that clinical results ... symptoms were,stabilized in patients with mild-to-moderate Alzheimer,s disease (AD) ...
Cached Medicine Technology:Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma 2Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma 3Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma 4Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress 2Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress 3Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress 4
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... 4 Judie Brown, president of American ... to an interview in which Archbishop Raymond Burke, ... court, stated: (Logo: http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) "There,s not ... after admonition, supports pro-abortion legislation is not to ...
... Inc. (Nasdaq: IDEV ) (the "Company") today announced ... fiscal 2009, ended December 31, 2008. The Company reported revenues ... million or $0.10 per share for the quarter ended December ... and a consolidated net loss of $14.7 million or $0.19 ...
... Rev. Larry Snyder, president of Catholic Charities ... the East Room of the White House as the ... Reauthorization Act of 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20081008/CCUSALOGO )The ... care access to children whose families do not qualify ...
... The Elton John AIDS Foundation announced today that ... Annual Elton John AIDS Foundation (EJAF) Academy Awards(R) Viewing ... Design Center in Los Angeles. The event will be ... will be co-sponsored by Chopard, Jo & Raffy Manoukian, ...
... Holdings, Inc.,(NYSE: HRC ), announced unaudited ... 31, 2008. Results included revenue of $351.6 ... $341.4 million in the prior year,comparable period. On ... Net income from continuing operations was $14.2 million, ...
... Tax Little Cigars at Cigarette Equivalent for First TimeWASHINGTON, ... indicates a dramatic increase in the use of cigarillos ... trend given the popularity of these products with young ... According to the data, over a 10-year period from ...
Cached Medicine News:Health News:American Life League: Vatican Says Bishops Must Refuse Communion to Pro-Abortion Politicians 2Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 2Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 3Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 4Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 5Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 6Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 7Health News:Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results 8Health News:Catholic Charities USA President Joins President Obama at Signing of Children's Health Insurance Legislation 2Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 2Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 3Health News:Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party 4Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 2Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 3Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 4Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 5Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 6Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 7Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 8Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 9Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 10Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 11Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 12Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 13Health News:Hill-Rom Reports First Quarter Revenue Growth of 3.0 Percent to $352 Million and Earnings Per Fully Diluted Share From Continuing Operations of $0.23, an Increase of 15.0 Percent From the Prior Year 14Health News:Little Cigar Consumption on the Rise, While Cigarette Use Declines 2Health News:Little Cigar Consumption on the Rise, While Cigarette Use Declines 3Health News:Little Cigar Consumption on the Rise, While Cigarette Use Declines 4
Electric high speed system....
Compressor-cooled plate used to keep blocks cold while sectioning....
... CO-Oximeter Control (Bayer 800 Series) is ... monitoring the performance of blood gas, ... 270 and 800 series) instrumentation. This ... Bayer 800 Rapidlab Series instruments in ...
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: